Allogeneic transplantation outcomes amongst a contemporary cohort of high-risk myelodysplastic syndrome and acute myeloid leukemia patients aged ≥70 years

Allogeneic hematopoietic stem cell transplantation (HSCT) is an integral therapy for patients with hematological malignancies, myelodysplasia, and bone marrow failure. Its use has been increasing over the past decade, as understanding of the treatment and its related toxicities has led to changes in...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Curtis Lachowiez, Rachel J. Cook, Brandon Hayes-Lattin, Richard T. Maziarz, Uma Borate, Elie Traer, Jessica Leonard, Laura Newell, Kim-Hien Dao, Gabrielle Meyers
Format:	Artigo
Jezik:	Inglês
Izdano:	Wolters Kluwer Medknow Publications 2019-01-01
Serija:	Hematology/Oncology and Stem Cell Therapy
Teme:	acute myeloid leukemia allogeneic stem cell transplant bone marrow transplant flt-3 hypomethylating agent induction chemotherapy leukemia myelodysplastic syndrome targeted therapy
Online dostop:	https://journals.lww.com/10.1016/j.hemonc.2019.01.002
Oznake:	Označite Brez oznak, prvi označite!